# Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities

> **NCT05714592** · NA · UNKNOWN · sponsor: **Centre Hospitalier Universitaire, Amiens** · enrollment: 300 (estimated)

## Conditions studied

- Myeloproliferative Neoplasm
- Optical Genome Mapping
- Cytogenetics
- Clonality
- Prognostic Stratification

## Interventions

- **OTHER:** Blood sample

## Key facts

- **NCT ID:** NCT05714592
- **Lead sponsor:** Centre Hospitalier Universitaire, Amiens
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-27
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2023-02-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05714592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05714592, "Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05714592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*